TickerFacts.

Structure Therapeutics Inc. (GPCR): Capital Expenditures

Annual figures by period end, from SEC filings.

$3.61M
Year ended 2025-12-31
$4.21M
Trailing 12 months to 2026-06-30
+185.7%
3-year compound annual growth
2022-12-31: $155.0K2023-12-31: $2.17M2024-12-31: $1.29M2025-12-31: $3.61M$3.61M
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$3.61M+180.2%2026-02-26, From 2025-01-01
2024-12-31$1.29M-40.5%2026-02-26, From 2024-01-01
2023-12-31$2.17Mn/m2026-02-26, From 2023-01-01
2022-12-31$155.0Kn/a2024-03-08, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Structure Therapeutics Inc. (GPCR)2025-12-31$3.61M+180.2%
Acadia Pharmaceuticals Inc (ACAD)2025-12-31$4.69M+796.7%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$452.0K-75.2%
Amphastar Pharmaceuticals, Inc. (AMPH)2025-12-31$34.88M-15.0%
Innoviva, Inc. (INVA)2025-12-31$1.13M+318.9%
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31$6.00M-14.3%
Collegium Pharmaceutical, Inc (COLL)2025-12-31$1.74M+5.3%
Phibro Animal Health Corp (PAHC)2026-06-30$59.09M+54.3%
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$1.34M+84.6%

Compare GPCR, ACAD, LGND, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗